Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA advisory on contaminated supplements

This article was originally published in The Tan Sheet

Executive Summary

FDA warns consumers not to purchase or consume several dietary supplements manufactured by NVE Pharmaceuticals and distributed by Norcross, Ga.-based Hi-Tech due to contamination with Rx erectile dysfunction ingredient tadalafil (Eli Lilly's Cialis). In a June 20 release, FDA notes Sigra, Stamina Rx, Stamina Rx for Women, Y-Y, Spontane ES and Uroprin, which claim to increase stamina and performance, actually pose health risks because interaction between certain Rx drugs and tadalafil "may cause a drastic lowering of blood pressure." This is of particular concern since erectile dysfunction "is often a common problem in people with diabetes, hypertension," ischemic heart disease and who smoke, FDA says. Agency notes its Office of Criminal Investigations executed concurrent federal search warrants in Georgia and New Jersey, where NVE is based, after discovering the supplements...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel